ReviewCells2019
Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models.
Review in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 170 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
170 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Application and prospect of organoid technology in breast cancer.Frontiers in immunology · 2024Pooled it
- Comparison of Cell Line-Derived and Patient-Derived Xenograft Technologies in Oncology (Review).Bulletin of experimental biology and medicine · 2026Article
- Article
- Preclinical Models of Bladder Cancer: Barrier, Metabolic, and Translational Susceptibility.Pharmaceuticals (Basel, Switzerland) · 2026Review
- IL-8 blockade enhances anti-PD-1 therapeutic activity in renal cell carcinoma in a next-generation patient-derived xenograft model.iScience · 2026Article
- Transgenic expression of human signal regulatory protein alpha (SIRPα) in BALB/c Rag2Transgenic research · 2026Article
- Preclinical antitumor evaluation of a tetrahydrocannabinol and cannabidiol (1:6) cannabis extract in an MCF-7 xenograft model of estrogen receptor-positive breast cancer.Veterinary world · 2026Article
- Pathological insights of human CD34+ hematopoietic stem cell-engrafted NSG mice: Implications for the safety assessment of cancer immunotherapy drugs.Veterinary pathology · 2026Article
- Recapitulating patient-to-patient colorectal cancer tumor heterogeneity using patient-derived xenograft cells in an engineered tissue model.Acta biomaterialia · 2026Article
- Macrophage plasticity in the osteosarcoma tumor microenvironment: opportunities and challenges for immunotherapy.Journal of cancer research and clinical oncology · 2026Review
- A novel hairless highly immunodeficient mice model optimized for in vivo imaging.Laboratory animal research · 2026Article
- Organoid-based systems for biomedical innovation: advances in disease modeling, drug screening, and precision medicine.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Treatment of acute myeloid leukemia models by targeting a cell surface RNA-binding protein.Nature biotechnology · 2026Article
- The application of experimental models for the drug discovery for digestive tumors.Molecular cancer · 2026Review
- Harnessing PDX and PDX 2.0: the next-generation paradigm for precision oncology and translational breakthroughs.Molecular cancer · 2026Review
- Therapeutic Advances of Curcumin and Nanocurcumin in Glioblastoma: Molecular Targets, Bioavailability, and Drug Delivery.Nutrients · 2026Review
- Picosecond infrared laser mass spectrometry for 10-second identification of lymphoproliferative imposter tumours in patient-derived xenografts.Scientific reports · 2026Article
- From 2D cultures to 3D systems: evolving cancer models at the interface of functional precision medicine and theranostics.Theranostics · 2026Review
- A Novel Magnetically Targeted Intramedullary (MagIC-TI) Xenograft Model for Precise Leukemia Modeling and Drug Resistance Evaluation in the Bone Marrow Niche.Journal of immunology research · 2026Article
- Tools and Technologies for Studying Cancer Metabolism.Cancer treatment and research · 2026Review
110 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patient-derived xenograft (PDX) models are created by engraftment of patient tumor tissues into immunocompetent mice. Since a PDX model retains the characteristics of the primary patient tumor including gene expression profiles and drug responses, it has become the most reliable in vivo human cancer model. The engraftment rate increases with the introduction of Non-obese diabetic Severe combined immunodeficiency (NOD/SCID)-based immunocompromised mice, especially the NK-deficient NOD strains NOD/SCID/interleukin-2 receptor gamma chain(IL2Rγ)
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.